Titrated baclofen for high-risk alcohol consumption: A randomized placebocontrolled trial in outpatients with one-year follow up, Addiction, 2019. ,
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen, and topiramate, Addiction, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01696955
, Lancet Psychiatry, vol.5, pp.961-962, 2018.
Restoring invisible and abandoned trials: a call for people to publish the findings, Bmj, p.346, 2013. ,
Equipoise and the ethics of clinical research, N Engl J Med, vol.317, pp.141-145, 1987. ,
, International guide for monitoring alcohol consumption and related harm, 2000.
Traitement de l'alcoolisme -Essai thérapeutique pragmatique randomisé, en double insu pendant un an en milieu ambulatoire du baclofène versus placebo. SFA, 2017. ,
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between, Pharmacoepidemiology and drug safety, vol.27, pp.1239-1248, 2009. ,
, , 2018.
Better reporting of harms in randomized trials: an extension of the CONSORT statement, Annals of internal medicine, vol.141, pp.781-788, 2004. ,